RPG Investment Advisory’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.58M Buy
260,620
+31,355
+14% +$1.49M 1.16% 39
2025
Q4
$11.7M Buy
229,265
+76,691
+50% +$3.92M 1.32% 32
2025
Q3
$8.47M Buy
152,574
+17,662
+13% +$1.03M 1% 41
2025
Q2
$9.31M Sell
134,912
-50,226
-27% -$3.42M 1.16% 37
2025
Q1
$12.9M Buy
185,138
+101,994
+123% +$8.42M 0.92% 47
2024
Q4
$7.15M Buy
83,144
+24,758
+42% +$2.68M 0.96% 46
2024
Q3
$6.95M Buy
+58,386
New +$7.79M 0.99% 47

Other funds holding NVO

RPG Investment Advisory's NVO Position: Q1 2026 in Review

RPG Investment Advisory increased its Novo Nordisk (NVO) stake by 14% in Q1 2026, buying an estimated $1.49M and bringing the position to 260,620 shares worth $9.58M. The position accounts for 1.16% of the portfolio, ranked #39.

RPG Investment Advisory first reported a position in NVO in Q3 2024 and has held it in 7 quarters since. The position peaked at $12.9M in Q1 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • RPG Investment Advisory held 260,620 shares of Novo Nordisk worth $9.58M as of Q1 2026.
  • RPG Investment Advisory bought 31,355 Novo Nordisk shares in Q1 2026, an estimated $1.49M.
  • Novo Nordisk made up 1.16% of RPG Investment Advisory's portfolio in Q1 2026, its #39 holding.
  • RPG Investment Advisory first reported a position in Novo Nordisk in Q3 2024 and has held it in 7 quarters since.
  • RPG Investment Advisory's Novo Nordisk position peaked at $12.9M in Q1 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on RPG Investment Advisory's 13F filing for Q1 2026, filed 14 May 2026.